Do we need to improve pharmacological approaches to treat insomnia in patients with opioid use disorder?

There is an absence of clear guidance on how to address insomnia among individuals with OUD. Improved pharmacotherapies targeting this pathology are critical not only for enhancing quality of life but also the success of OUD treatment outcomes. Large, rigorous clinical trials are sorely needed to improve sleep medication prescribing guidelines in this population.